- Your Allergy Meds Come With Hazards: Be Aware
- Vaping Linked to Earlier Onset of Asthma
- FDA Approves New Drug for Deadly Lung Cancer
- U.S. Justice Department Moves to Reclassify Weed as Less Risky Drug
- Global Life Expectancy Could Rise By More Than 4 Years by 2050
- Most Cancer Treatments Near End of Life Are Useless: Study
- Brain’s ‘Food Smell’ Circuitry Might Drive Overeating
- The More Kids Use Social Media, The More They’re Likely to Vape
- Men Are More Debilitated by Diabetes Than Women
- Is Your Child Ready for Summer Sleepaway Camp?
Onivyde Approved for Advanced Pancreatic Cancer
The injected drug Onivyde (irinotecan liposome) has been approved by the U.S. Food and Drug Administration for pancreatic cancer that has either spread or is surgically untreatable.
Pancreatic cancer is difficult to treat, the agency said, citing U.S. Government estimates that 48,960 new cases would be diagnosed this year and 40,560 would die from it.
The new drug’s effectiveness was evaluated in clinical studies involving 417 people with advanced pancreatic cancer. People treated with a combination of Onivyde and the anti-cancer drugs fluorouracil or leucovorin lived an average of 6.1 months, compared to 4.2 months among those treated with fluorouracil or leucovorin alone, the FDA said.
Onivyde’s most common side effects include diarrhea, fatigue, vomiting, loss of appetite, mouth inflammation and fever. The drug’s label also warns that it may cause severe diarrhea and a drop in cells designed to fight infections, the agency said.
Onivyde is marketed by Merrimack Pharmaceuticals, based in Cambridge, Mass.
More information
Visit the FDA to learn more.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.